Products for Research Use Only

Lalistat 1

CAT: 0804-HY-116815-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-116815-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Lalistat 1 is a potent, selective, and competitive inhibitor of lysosomal acid lipase (LAL) and against purified human LAL (phLAL) with an IC50 of 68 nM. Lalistat 1 is a inhibitor of immunoglobulin A1 protease (IgA1P) proteases for H. influenzae, has less effects on other serine hydrolases (trypsin or β-lactamase, etc.) . Lalistat 1 can be used for the research of niemann-pick type C (NPC) disease[2].
CAS Number
501104-16-1
Product Name Alternative
AM152
UNSPSC
12352005
Hazard Statement
H302, H312, H315, H319, H332, H335
Target
Bacterial; Beta-lactamase
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-immunoregulation
Field of Research
Infection; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/lalistat-1.html
Purity
99.75
Solubility
DMSO : 20 mg/mL (ultrasonic; warming)
Smiles
O=C(N1CCOCC1)OC2=NSN=C2N3CCCCC3
Molecular Formula
C12H18N4O3S
Molecular Weight
298.37
Precautions
H302, H312, H315, H319, H332, H335
References & Citations
[1]Anton I Rosenbaum , et al. Thiadiazole carbamates: potent inhibitors of lysosomal acid lipase and potential Niemann-Pick type C disease therapeutics. J Med Chem . 2010 Jul 22;53 (14) :5281-9.|[2]Livia Shehaj, et al. Small-Molecule Inhibitors of Haemophilus influenzae IgA1 Protease.ACS Infect Dis. 2019 Jul 12;5 (7) :1129-1138.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported